The aim of this study was to investigate the adipocyte size and fate in subcutaneous fat (scAT) of cows diverging for genetic merit at mid lactation stage, when anabolic activity increases and animals are in a state of positive energy balance. Twenty mid lactation cows (180±20days in milk) grouped according to the Estimated Breeding Values (EBV) for milk yield in plus (EBVp) and minus (EBVm) variants were selected. Average of adipocytes area, proliferation and apoptotic labelling index as well as DLK-1 expression, a marker of pre-adipocytes, were immunohistochemically evaluated in scAT biopsies. In EBVp cows, the BCS was lower (P<0.01) whereas milk yield, protein, fat yield (P<0.001) and plasma free fatty acid concentration (P<0.05) were higher. The scAT of EBVp cows showed a significantly (P<0.001) higher frequency between 500 and 3000μm classes in comparison to EBVm cows, that showed a significantly (P<0.01) higher apoptotic labeling index. The immunohistochemical reaction showed DLK-1 positivity in scAT of EBVp cows. Taking together, the data indicate a link between milk yield genetic merit of cows, scAT morphology and function, suggesting greater dynamics and metabolic flexibility in EBVp cows.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tice.2016.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Conservation genomics within government led conservation planning: an Australian case study exploring cost and benefit for threatened flora.
Ann Bot
January 2025
Research Centre for Ecosystem Resilience, Botanic Gardens of Sydney, Sydney, NSW, 2000, Australia.
The importance of conserving plant genetic diversity has been recognised since the 1980's, but genetic research tools for improving conservation remain largely absent from standard planning. Using an Australian case study framework of the New South Wales Government's Saving our Species program, we outline the costs and benefits associated with conducting genomic analysis within a conservation strategy to inform for example, taxonomic resolution, targeted monitoring, translocations and ex situ collections. Despite a reported sentiment that costs are prohibitive, our study identified that where genetics reports have been provided (32 to date), the cost of genetic sampling, analysis and advice is less than 10% of the total Government investment (SoS program) and will continue decreasing proportionally throughout the years as other management occurs.
View Article and Find Full Text PDFGenomic exploration of the journey of Plasmodium vivax in Latin America.
PLoS Pathog
January 2025
REHABS, International Research Laboratory, CNRS-NMU-UCBL, George Campus, Nelson Mandela University, George, South Africa.
Plasmodium vivax is the predominant malaria parasite in Latin America. Its colonization history in the region is rich and complex, and is still highly debated, especially about its origin(s). Our study employed cutting-edge population genomic techniques to analyze whole genome variation from 620 P.
View Article and Find Full Text PDFDifferent Breeding Values Under Uniform Environmental Condition for Milk Production Yield Traits in Holstein-Friesian Cows.
Animals (Basel)
December 2024
Department of Animal Sciences, Albert Kázmér Faculty of Agriculture and Food Sciences, Széchenyi István University, Vár t. 2, H-9200 Mosonmagyaróvár, Hungary.
In this study, 1,616,549 Holstein-Friesian females were genotyped for genomic evaluation of genetic merit (BV). Genotyping was performed using the EuroGenomics MD v3.0 chipset on the Illumina microarray scanner platform operated by an accredited Illumina laboratory.
View Article and Find Full Text PDFLentivirus-mediated gene therapy for Fabry disease: 5-year End-of-Study results from the Canadian FACTs trial.
Clin Transl Med
January 2025
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Background: Fabry disease is an X-linked lysosomal storage disorder due to a deficiency of α-galactosidase A (α-gal A) activity. Our goal was to correct the enzyme deficiency in Fabry patients by transferring the cDNA for α-gal A into their CD34+ hematopoietic stem/progenitor cells (HSPCs). Overexpression of α-gal A leads to secretion of the hydrolase; which can be taken up and used by uncorrected bystander cells.
View Article and Find Full Text PDFStage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.
Invest New Drugs
January 2025
Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan.
The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation between stage IVA or lower and stage IVB EGFR mutation-positive lung cancers, focusing on differences in pretreatment co-occurring genetic alterations in circulating tumor DNA. This was a secondary analysis of the ELUCIDATOR study, a multicenter prospective observational study in Japan that assessed the mechanisms underlying resistance to osimertinib as a first-line treatment for advanced NSCLC with EGFR mutations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!